C. İNCİR Et Al. , "Evaluation of the Impact of SRD5A2 Gene Polymorphisms on Dutasterid Efficacy and Safety in Patients with Bladder Cancer," BRITISH JOURNAL OF PHARMACOLOGY , pp.1335, 2023
İNCİR, C. Et Al. 2023. Evaluation of the Impact of SRD5A2 Gene Polymorphisms on Dutasterid Efficacy and Safety in Patients with Bladder Cancer. BRITISH JOURNAL OF PHARMACOLOGY , 1335.
İNCİR, C., GÜMÜŞTEKİN, M., Korhan, P., ÖZER, M. S., SARIKAYA, A. E., Bozkurt, O., ... Atabey, S. N.(2023). Evaluation of the Impact of SRD5A2 Gene Polymorphisms on Dutasterid Efficacy and Safety in Patients with Bladder Cancer. BRITISH JOURNAL OF PHARMACOLOGY , 1335.
İNCİR, CANET Et Al. "Evaluation of the Impact of SRD5A2 Gene Polymorphisms on Dutasterid Efficacy and Safety in Patients with Bladder Cancer," BRITISH JOURNAL OF PHARMACOLOGY , 1335, 2023
İNCİR, CANET Et Al. "Evaluation of the Impact of SRD5A2 Gene Polymorphisms on Dutasterid Efficacy and Safety in Patients with Bladder Cancer." BRITISH JOURNAL OF PHARMACOLOGY , pp.1335, 2023
İNCİR, C. Et Al. (2023) . "Evaluation of the Impact of SRD5A2 Gene Polymorphisms on Dutasterid Efficacy and Safety in Patients with Bladder Cancer." BRITISH JOURNAL OF PHARMACOLOGY , p.1335.
@article{article, author={CANET İNCİR Et Al. }, title={Evaluation of the Impact of SRD5A2 Gene Polymorphisms on Dutasterid Efficacy and Safety in Patients with Bladder Cancer}, journal={BRITISH JOURNAL OF PHARMACOLOGY}, year=2023, pages={1335} }